Skip to main content

From DNA to TOX drug substance in 5 months and IND in 11 months. Speed to clinic and to market is increasingly gaining importance among biopharmaceutical drug developers. Companies ranging from small Biotech to large Pharma are constantly driving to shorten development time and gain faster approval for their therapies that may address unmet medical needs.

Read how Lonza´s Ibex Design 2.0 Program acceleratoes time to IND right here.

Share this article

View all news

Sign up to receive our newsletter in your inbox.